Neurocrine Biosciences (NBIX) Total Current Liabilities (2010 - 2026)

Neurocrine Biosciences has reported Total Current Liabilities for 17 years, with the latest figure at $831.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 59.06% year-over-year to $831.7 million; the trailing twelve-month figure through Mar 2026 stood at $831.7 million (up 59.06% YoY), and the FY2025 full-year result was $743.4 million, up 46.43% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $831.7 million, up from $743.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $831.7 million in Q1 2026, with the low at $253.5 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $540.9 million across 5 years, with a median of $537.7 million in 2022.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 118.76% — and 2024, when it slumped 37.87%.
• Neurocrine Biosciences' Total Current Liabilities stood at $537.7 million in 2022, then increased by 21.78% to $654.8 million in 2023, then fell by 22.46% to $507.7 million in 2024, then surged by 46.43% to $743.4 million in 2025, then climbed by 11.88% to $831.7 million in 2026.
• The last three Total Current Liabilities figures came in at $831.7 million (Q1 2026), $743.4 million (Q4 2025), and $638.0 million (Q3 2025), per Business Quant data.